Table 1.
Baseline clinical characteristics.
| Patient Characteristics | N = 13 |
|---|---|
| Mean age, years ± SD | 81 ± 4 |
| Gender-female, n (%) | 11 (85) |
| BSA, m2 ± SD | 1.7 ± 0.2 |
| STS score, % median (Q1–Q3) | 5.8 (3.8–7.7) |
| EuroScore II, % ± SD | 8 ± 4 |
| Diabetes, n (%) | 4 (31) |
| Hypertension, n (%) | 12 (92) |
| Hyperlipidaemia, n (%) | 5 (38) |
| Coronary artery disease, n (%) | 4 (31) |
| Smoking, n (%) | 1 (8) |
| Atrial fibrillation, n (%) | 13 (100) |
| History of cerebrovascular insult, n (%) | 2 (15) |
| COPD, n (%) | 2 (15) |
| CIED, n (%) | 4 (31) |
| Previous TAVI implantation, n (%) | 3 (23) |
| NYHA functional class III or more, n (%) | 13 (100) |
| Medications | |
| Salicylic Acid, n (%) | 3 (23) |
| Novel oral anticoagulant, n (%) | 8 (62) |
| Warfarin, n (%) | 4 (31) |
| Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, n (%) | 6 (46) |
| Digoxin, n (%) | 3 (23) |
| Calcium channel blocker, n (%) | 3 (23) |
| Beta-blocker, n (%) | 11 (85) |
| Diuretic, n (%) | 13 (100) |
BSA: Body Surface Area; CIED: cardiac implantable electronic device; COPD: chronic obstructive pulmonary disease; NYHA: New York Heart Association; STS: Society of Thoracic Surgeons Score; TAVI: Transcatheter aortic valve implantation.